Lipella Pharmaceuticals Inc.
LIPO
$2.52
$0.031.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.79% | -22.77% | 27.84% | 23.64% | -20.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.79% | -22.77% | 27.84% | 23.64% | -20.00% |
| Cost of Revenue | 133.88% | 25.61% | -37.44% | 21.46% | -5.00% |
| Gross Profit | -166.56% | -32.52% | 44.78% | -21.02% | -1.93% |
| SG&A Expenses | 42.00% | -21.42% | -31.58% | 2.38% | 1,130.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.09% | 5.41% | -35.28% | 13.39% | 66.65% |
| Operating Income | -98.92% | -7.57% | 39.55% | -12.28% | -103.06% |
| Income Before Tax | -109.28% | -9.14% | 39.03% | -11.61% | -89.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.28% | -9.14% | 39.03% | -11.61% | -89.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.28% | -9.14% | 39.03% | -11.61% | -89.31% |
| EBIT | -98.92% | -7.57% | 39.55% | -12.28% | -103.06% |
| EBITDA | -99.01% | -7.54% | -- | -- | -- |
| EPS Basic | -46.38% | 29.85% | 53.95% | 12.08% | -23.04% |
| Normalized Basic EPS | -46.39% | 29.86% | 53.96% | 12.08% | -23.02% |
| EPS Diluted | -45.57% | 29.85% | 54.31% | 13.98% | -23.72% |
| Normalized Diluted EPS | -46.39% | 29.86% | 53.96% | 12.08% | -23.02% |
| Average Basic Shares Outstanding | 42.98% | 55.60% | 32.41% | 26.96% | 53.84% |
| Average Diluted Shares Outstanding | 42.98% | 55.60% | 32.41% | 26.96% | 53.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |